Regeneron Pharmaceuticals Inc. (REGN)
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
REGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $95.24B
- P/E (TTM)
- 20.35
- Forward P/E
- 12.85
- EPS (TTM)
- $45.24
- Dividend yield
- 0.40% ($3.70)
- Ex-dividend date
- Nov 20, 2026
- 52-week range
- 591.52 – 991.73
- Day range
- 916.66 – 948.42
- Volume / Avg
- 877.67K / 805.45K
- Beta
- —
- Shares outstanding
- 101.63M
52-week range
REGN stock today
On Nov 20, REGN ended the session at $920.69, shedding $1.71 (0.19%), versus the S&P 500's 3.70% decline. At this level, REGN sits near the top of its 52-week range of $591.52 to $991.73: 7.2% below the high, set on Nov 4, 2026 and 55.6% above the low. REGN is up 19.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.8%.
At 20.4x trailing earnings, Regeneron Pharmaceuticals trades below the peer-group median of 33.1x. Its forward P/E of 12.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Regeneron Pharmaceuticals pays an annual dividend of $3.70 per share, a 0.40% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Regeneron Pharmaceuticals
Company profileRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Leonard S. Schleifer M.D., Ph.D.
- Headquarters
- Tarrytown, NY
- Employees
- 15,410
- IPO year
- 1991
- Website
- regeneron.com
Financial highlights
Full financialsIn fiscal 2025, Regeneron Pharmaceuticals generated $14.34 billion in revenue, up 1.0% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $4.50 billion (+2.1% year over year), for a net margin of 31.4% versus a median of 35.6% in the prior 5 years. Operating margin was 24.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Growth | +0.99% | +8.27% | +7.76% | -24.26% | +89.14% |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| EPS (diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$991.00+7.64%
- Strong buy 4
- Buy 15
- Hold 9
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 30, 2026
- EPS actual vs est.
- $18.45 vs $13.76
- Surprise
- +34.08%
Dividends
Dividend history- Annual dividend
- $3.70
- Dividend yield
- 0.40%
- Last payment
- $0.94
- Ex-dividend date
- Nov 20, 2026
- Pay date
- Dec 3, 2026
REGN news
All REGN news- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- Here's Why Regeneron (REGN) is a Strong Momentum StockNasdaq
- 2 Growth Stocks to Buy in November Without Any HesitationNasdaqVRTX, REGN
- iShares Biotechnology ETF Experiences Big InflowNasdaqIBB, REGN, ARGX, ONC
- REGN Gets FDA Nod for Livsayis in Generalized Myasthenia GravisNasdaqREGN, ALNY, VCEL, ETON
- Regeneron Wins FDA Approval For Livsayis In Generalized Myasthenia GravisNasdaqREGN, MKC.V
- Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous DosingGlobeNewswire
- Regeneron Wins EC Clearance for Libtayo Dosing FlexibilityNasdaqREGN, SNY, CTMX
Regeneron Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs REGN |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs REGN |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs REGN |
| TAKTakeda Pharmaceutical Company Limited ADR | 21.77 | +1.68% | $69.55B | vs REGN |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs REGN |
| TEVATeva Pharmaceutical Industries Limited | 39.23 | +1.79% | $45.77B | vs REGN |
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs REGN |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs REGN |
Indexes, lists and sector
Index membership
Appears in lists
Regeneron Pharmaceuticals stock FAQ
What is Regeneron Pharmaceuticals's stock price today?
REGN last traded at $920.69 as of Nov 20, 4:00 PM EST, down 0.19% on the day. Prices are delayed at least 15 minutes.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. Regeneron Pharmaceuticals pays $3.70 per share annually, a 0.40% yield. The most recent dividend of $0.94 had an ex-dividend date of Nov 20, 2026.
What is REGN's P/E ratio?
REGN trades at a trailing P/E ratio of 20.35 and a forward P/E of 12.85, compared with a median of 33.1 for its closest peers.
Is Regeneron Pharmaceuticals in the S&P 500?
Yes. Regeneron Pharmaceuticals (REGN) is a constituent of the S&P 500 index.
Who is Regeneron Pharmaceuticals's CEO?
Dr. Leonard S. Schleifer M.D., Ph.D. is the chief executive officer of Regeneron Pharmaceuticals Inc., which has about 15,410 employees.
What is the REGN 52-week high?
The 52-week high for REGN is $991.73 and the 52-week low is $591.52. The stock is currently 7.2% below its high.